对于FLT3突变的急性髓系白血病，无论是低强度还是高强度方案，异基因移植都能为FMS样酪氨酸激酶3（FLT3）抑制剂带来额外益处。
Allogeneic transplantation provides added benefit to FMS-like tyrosine kinase 3 (FLT3) inhibitors for both low-intensity and high-intensity regimens in FLT3-mutated acute myeloid leukemia.
作者信息
Becker Pamela S
机构信息
Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Department of Hematologic Malignancies Translational Science, City of Hope National Medical Center, Duarte, California, USA.
出版信息
Cancer. 2025 Jul 15;131(14):e35973. doi: 10.1002/cncr.35973.
Abstract
This editorial describes the current status of FLT3 inhibitors in the treatment of AML and reviews a retrospective study of single institution data for use of FLT3 inhibitors with both intensive and low intensity treatment of AML. For patients who received low intensity regimens, there was benefit to the combined inclusion of FLT3 inhibitor and venetoclax in triple drug regimens, as well as improved outcomes with allogeneic transplant for all FLT3 mutated patients.
摘要
这篇社论描述了FLT3抑制剂在急性髓系白血病（AML）治疗中的现状，并回顾了一项关于单机构数据的回顾性研究，该研究涉及FLT3抑制剂在AML强化和低强度治疗中的应用。对于接受低强度方案治疗的患者，在三联药物方案中联合使用FLT3抑制剂和维奈克拉有获益，并且所有FLT3突变患者接受异基因移植后的预后有所改善。
相似文献
1
Allogeneic transplantation provides added benefit to FMS-like tyrosine kinase 3 (FLT3) inhibitors for both low-intensity and high-intensity regimens in FLT3-mutated acute myeloid leukemia.对于FLT3突变的急性髓系白血病，无论是低强度还是高强度方案，异基因移植都能为FMS样酪氨酸激酶3（FLT3）抑制剂带来额外益处。
Cancer. 2025 Jul 15;131(14):e35973. doi: 10.1002/cncr.35973.
2
Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.FLT3-ITD阳性急性髓系白血病的预后：异基因干细胞移植和酪氨酸激酶抑制剂治疗的影响
J Cancer Res Clin Oncol. 2017 Feb;143(2):337-345. doi: 10.1007/s00432-016-2290-5. Epub 2016 Oct 24.
3
A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia.一项关于新诊断的、FMS样酪氨酸激酶3（FLT3）突变的急性髓系白血病患者跨时间和治疗方案的结局的回顾性研究。
Cancer. 2025 Mar 15;131(6):e35813. doi: 10.1002/cncr.35813.
4
Impact of FLT3 inhibitors on the outcomes of FLT3-ITD mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant: A systematic review and meta-analysis.FLT3抑制剂对异基因造血干细胞移植后FLT3-ITD突变急性髓系白血病预后的影响：一项系统评价和荟萃分析。
Leuk Res. 2025 Aug;155:107724. doi: 10.1016/j.leukres.2025.107724. Epub 2025 Jun 2.
5
Is allogeneic transplantation really the best treatment for FLT3/ITD-positive acute myeloid leukemia? A systematic review.异基因移植真的是FLT3/ITD阳性急性髓系白血病的最佳治疗方法吗？一项系统评价。
Clin Transplant. 2015 Feb;29(2):149-60. doi: 10.1111/ctr.12495. Epub 2015 Jan 2.
6
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.异基因造血干细胞移植后使用索拉非尼维持治疗FMS样酪氨酸激酶3内部串联重复急性髓系白血病的I期试验
Biol Blood Marrow Transplant. 2014 Dec;20(12):2042-8. doi: 10.1016/j.bbmt.2014.09.007. Epub 2014 Sep 17.
7
[Hematopoietic cell transplantation for FLT3-mutated acute myeloid leukemia].[FLT3突变型急性髓系白血病的造血细胞移植]
Rinsho Ketsueki. 2022;63(9):1242-1251. doi: 10.11406/rinketsu.63.1242.
8
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.伴有 FLT3-ITD 和 IDH 突变的急性髓系白血病患者的临床特征和结局。
Cancer. 2021 Feb 1;127(3):381-390. doi: 10.1002/cncr.33293. Epub 2020 Oct 29.
9
Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.索拉非尼作为 Fms 样酪氨酸激酶 3 突变型急性髓系白血病异基因造血干细胞移植后维持治疗药物的疗效和可行性：更新。
Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):506-508. doi: 10.1016/j.clml.2019.04.004. Epub 2019 Apr 18.
10
Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia.奈拉替尼，一种新型的 FLT3 抑制剂，克服了急性髓系白血病的继发性耐药。
Cell Commun Signal. 2024 Jul 8;22(1):355. doi: 10.1186/s12964-024-01729-0.
本文引用的文献
1
A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia.一项关于新诊断的、FMS样酪氨酸激酶3（FLT3）突变的急性髓系白血病患者跨时间和治疗方案的结局的回顾性研究。
Cancer. 2025 Mar 15;131(6):e35813. doi: 10.1002/cncr.35813.
2
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of .吉特替尼作为伴有. 内部串联重复突变的 AML 移植后维持治疗。
J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12.
3
Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.Crenolanib 联合强化化疗治疗新诊断的 FLT3 突变型 AML 成人患者
J Clin Oncol. 2024 May 20;42(15):1776-1787. doi: 10.1200/JCO.23.01061. Epub 2024 Feb 7.
4
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory -Mutated AML.阿扎胞苷、维奈托克和吉特替尼治疗新诊断和复发/难治性 - 突变 AML。
J Clin Oncol. 2024 May 1;42(13):1499-1508. doi: 10.1200/JCO.23.01911. Epub 2024 Jan 26.
5
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.Quizartinib 联合化疗治疗新诊断的 FLT3 内部串联重复阳性急性髓系白血病患者（QuANTUM-First）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2023 May 13;401(10388):1571-1583. doi: 10.1016/S0140-6736(23)00464-6. Epub 2023 Apr 25.
6
DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.DNA 测序检测造血细胞移植前急性髓系白血病成人患者的残留疾病。
JAMA. 2023 Mar 7;329(9):745-755. doi: 10.1001/jama.2023.1363.
7
Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome.通过高灵敏度聚合酶链反应-下一代测序评估的移植前FLT3-ITD微小残留病可确定移植后的临床结局。
Blood. 2022 Dec 1;140(22):2407-2411. doi: 10.1182/blood.2022016567.
8
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.一线 venetoclax 联合治疗老年 AML 患者后的反应和治疗失败的分子模式。
Blood. 2020 Mar 12;135(11):791-803. doi: 10.1182/blood.2019003988.
9
Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML.吉特替尼与化疗用于治疗复发/难治性 - 突变型 AML。
N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688.
10
getITD for FLT3-ITD-based MRD monitoring in AML.获取用于急性髓系白血病中基于FLT3-ITD的微小残留病监测的ITD。
Leukemia. 2019 Oct;33(10):2535-2539. doi: 10.1038/s41375-019-0483-z. Epub 2019 May 14.
Zotero 插件